{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T22:49:10Z","timestamp":1708382950261},"reference-count":51,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"This research was funded by the National Heart, Lung and Blood Institute, Cure Sickle Cell initiative"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2022,8,18]]},"DOI":"10.1080\/14737167.2022.2060823","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:09:50Z","timestamp":1648832990000},"page":"891-911","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["A landscape analysis and discussion of value of gene therapies for sickle cell disease"],"prefix":"10.1080","volume":"22","author":[{"given":"Dalyna","family":"Quach","sequence":"first","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boshen","family":"Jiao","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirban","family":"Basu","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington"},{"name":"Department of Health Services, University of Washington, Seattle, Washington, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Bender","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle"},{"name":"Department of Pediatrics, University of Washington, and Clinical Research Division,Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Hankins","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences and Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Devine","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington"},{"name":"Department of Health Services, University of Washington, Seattle, Washington, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56947-0_13"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609677"},{"issue":"6","key":"cit0003","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jval.2019.01.012","volume":"22","author":"Pearson SD.","year":"2019","journal-title":"Value Health"},{"key":"cit0004","unstructured":"Cure sickle cell initiative | advancing research in sickle cell disease | cure sickle cell. curesickle.org. https:\/\/curesickle.org\/. Published. 2021 2021 Jun 24."},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1590\/s1679-45082017rb4024"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01235-7"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2017.10.010"},{"issue":"10","key":"cit0008","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/hum.2016.107","volume":"27","author":"Yu K","year":"2016","journal-title":"Human Gene Therapy"},{"issue":"10","key":"cit0009","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2016.103","volume":"27","author":"Bernardo M","year":"2016","journal-title":"Human Gene Therapy"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.014"},{"key":"cit0011","unstructured":"Centers for Disease Control and Prevention. Data & Statistics on Sickle Cell Disease. Centers for Disease Control and Prevention. Published August 31, 2016. Accessed 2020 Dec 18. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.htm"},{"issue":"2","key":"cit0012","doi-asserted-by":"crossref","first-page":"021103","DOI":"10.7189\/jogh.08.021103","volume":"8","author":"Wastnedge E","year":"2018","journal-title":"Glob Health"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012838"},{"key":"cit0015","unstructured":"American Society of Hematology; 2016. Rare patients with sickle cell disease live nearly twice as long as average. https:\/\/www.hematology.org\/newsroom\/press-releases\/2016\/rare-patients-with-sickle-cell-disease-live-nearly-twice-as-long-as-average. (Accessed: May 15, 2021)."},{"issue":"11","key":"cit0016","doi-asserted-by":"crossref","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","volume":"2","author":"Lubeck D","journal-title":"JAMA Network Open"},{"issue":"2","key":"cit0017","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/003335491613100221","volume":"131","author":"Paulukonis ST","year":"1974","journal-title":"Public Health Rep Wash DC"},{"issue":"2","key":"cit0018","first-page":"110","volume":"128","author":"Lanzkron S","year":"2013","journal-title":"433021"},{"key":"cit0019","author":"Bradt P","journal-title":"Institute for Clinical and Economic Review"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.04.003"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-618587"},{"issue":"1","key":"cit0022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/nyas.13024","volume":"1368","author":"Basak A","year":"2016","journal-title":"N Y Acad Sci"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711566105"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1126\/science.1211053"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-528067"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029392"},{"issue":"9","key":"cit0028","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","volume":"4","author":"Hsieh M","year":"2020","journal-title":"Blood Advances"},{"key":"cit0029","unstructured":"Businesswire. bluebird bio Announces Temporary Suspension on Phase 1\/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111). Businesswire.com. Published 2021. 2021 Jul 1. https:\/\/www.businesswire.com\/news\/home\/20210216005442\/en\/bluebird-bio-Announces-Temporary-Suspension-on-Phase-12-and-Phase-3-Studies-of-LentiGlobin-Gene-Therapy-for-Sickle-Cell-Disease-bb1111."},{"key":"cit0030","unstructured":"bluebird bio. Bluebird bio provides updated findings from reported case of Acute Myeloid Leukemia (AML) in lentiglobin for Sickle Cell Disease (SCD) gene therapy program. 2021. Accessed 2021 Jun 13. https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-provides-updated-findings-reported-case-acute."},{"key":"cit0031","unstructured":"bluebird bio. bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations; 2021. 2021 May 30. https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-provides-update-severe-genetic-disease-programs-and."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011488"},{"key":"cit0033","unstructured":"bluebird bio. bluebird bio announces the lifting of FDA clinical hold for sickle cell disease and \u03b2-Thalassemia Studies. 2021. Accessed 2021 Jun 13. https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-provides-updated-findings-reported-case-acute"},{"key":"cit0034","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2018 Feb 13).). Gene transfer for sickle cell disease. Identifier NCT03282656, http:\/\/clinicaltrials.gov\/ct\/show\/NCT03282656?order=1"},{"key":"cit0035","volume-title":"Poster presented at: American Society of Hematology Annual Meeting and Exposition","author":"Kanter J"},{"issue":"10","key":"cit0036","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/d41587-019-00026-3","volume":"37","author":"Harrison C","year":"2019","journal-title":"Nat Biotechnol"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.178"},{"issue":"11","key":"cit0038","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3324\/haematol.2017.169581","volume":"102","author":"Arnold S","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"cit0039","doi-asserted-by":"crossref","first-page":"e0229710","DOI":"10.1371\/journal.pone.0229710","volume":"15","author":"Saraf S","year":"2020","journal-title":"PloS one"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.204"},{"key":"cit0041","volume-title":"Cost-effectiveness in health and medicine","author":"Neumann PG","year":"2017","edition":"2"},{"key":"cit0042","first-page":"929","volume":"19","author":"Woods B","year":"2016","journal-title":"Initial Estimates and the Need for Further Research. Value in Health"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90405-1"},{"key":"cit0044","unstructured":"2020 Value Assessment Framework Proposed Changes. Institute for Clinical and Economic Review; 2019. 2021 May 30. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_VAF_Proposals_082119-1.pdf\n."},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.18378"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.7140"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.017"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.012"},{"key":"cit0049","unstructured":"Clinicaltrials.gov. Bone marrow transplantation vs standard of care in patients with severe sickle cell disease (BMT CTN 1503). Betheseda, MD: National Library of Medicine; 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02766465. (Accessed: May 25, 2021). NLM identifier: NCT02766465."},{"key":"cit0050","unstructured":"Clinicaltrials.gov. STRIDE Biorepository. Bethesda, MD: National Library of Medicine. 2017; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02843347. (Accessed May25, 2020). NLM Identifier: NCT02843347."},{"issue":"6","key":"cit0051","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamapediatrics.2020.7147","volume":"175","author":"Gene OP","year":"2021","journal-title":"JAMA Pediatr"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2022.2060823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T13:34:11Z","timestamp":1662644051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2022.2060823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8,18]]}},"alternative-id":["10.1080\/14737167.2022.2060823"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2022.2060823","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}